Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations

Lung Cancer

Volumn 87, Issue 3, 2015, Pages 311-317

  Yeo, Chang Dong ^a   Park, Ki Hoon ^a   Park, Chan Kwon ^a   Lee, Sang Haak ^a   Kim, Seung Joon ^a   Yoon, Hyung Kyu ^a   Lee, Youn Soo ^a   Lee, Eun Jung ^a   Lee, Kyo Young ^a   Kim, Tae Jung ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

DM; EGFR mutation; IGF 1R; Non small cell lung cancer; Progression free survival; TKI

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN C RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; DIABETES MELLITUS; DRUG RESPONSE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SMOKING; SQUAMOUS CELL LUNG CARCINOMA; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; COMORBIDITY; GENE EXPRESSION; GENETICS; LUNG NEOPLASMS; METASTASIS; MIDDLE AGED; MORTALITY; MUTATION; OUTCOME ASSESSMENT; PATHOLOGY; PROGNOSIS; RISK FACTOR; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COMORBIDITY; FEMALE; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; PATIENT OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84924049502     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.01.004     Document Type: Article

References (42)

1. Jett J.R., Carr L.L. Targeted therapy for non-small cell lung cancer. Am J Respir Crit Care Med 2013, 188:907-912.
2. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
3. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246.
4. Sequist L.V., Yang J.C., Yamamoto N., O'Byrne K., Hirsh V., Mok T., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31:3327-3334.
5. Ohashi K., Maruvka Y.E., Michor F., Pao W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol 2013, 31:1070-1080.
6. Gallagher E.J., LeRoith D. The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab 2010, 21:610-618.
7. Pollak M. Targeting insulin and insulin-like growth factor signalling in oncology. Curr Opin Pharmacol 2008, 8:384-392.
8. Kim J.S., Kim E.S., Liu D., Lee J.J., Solis L., Behrens C., et al. Prognostic implications of tumoral expression of insulin like growth factors 1 and 2 in patients with non-small-cell lung cancer. Clin Lung Cancer 2014, 15:213-221.
9. Langer C.J., Novello S., Park K., Krzakowski M., Karp D.D., Mok T., et al. Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. J Clin Oncol 2014, 32:2059-2066.
10. Singh P., Alex J.M., Bast F. Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer. Med Oncol 2014, 31:805.
11. Xue M., Cao X., Zhong Y., Kuang D., Liu X., Zhao Z., et al. Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors in cancer therapy: advances and perspectives. Curr Pharm Des 2012, 18:2901-2913.
12. Peled N., Wynes M.W., Ikeda N., Ohira T., Yoshida K., Qian J., et al. Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. Cell Oncol (Dordr) 2013, 36:277-288.
13. Barone B.B., Yeh H.C., Snyder C.F., Peairs K.S., Stein K.B., Derr R.L., et al. Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis. Diabetes Care 2010, 33:931-939.
14. Richardson L.C., Pollack L.A. Therapy insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol 2005, 2:48-53.
15. Barone B.B., Yeh H.C., Snyder C.F., Peairs K.S., Stein K.B., Derr R.L., et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008, 300:2754-2764.
16. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008, 8:915-928.
17. Lee J.Y., Jeon I., Lee J.M., Yoon J.M., Park S.M. Diabetes mellitus as an independent risk factor for lung cancer: a meta-analysis of observational studies. Eur J Cancer 2013, 49:2411-2423.
18. Luo J., Chen Y.J., Chang L.J. Fasting blood glucose level and prognosis in non-small cell lung cancer (NSCLC) patients. Lung Cancer 2012, 76:242-247.
19. Yeo C.D., Kim J.W., Kim K.H., Ha J.H., Rhee C.K., Kim S.J., et al. Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing. Lung Cancer 2013, 81:207-212.
20. Kim T.J., Park C.K., Yeo C.D., Park K., Rhee C.K., Kim J., et al. Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage. J Surg Oncol 2014, 110:245-251.
21. Gong Y., Yao E., Shen R., Goel A., Arcila M., Teruya-Feldstein J., et al. High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS ONE 2009, 4:e7273.
22. Jackman D., Pao W., Riely G.J., Engelman J.A., Kris M.G., Janne P.A., et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010, 28:357-360.
23. Ayoola A., Barochia A., Belani K., Belani C.P. Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update. Cancer Invest 2012, 30:433-446.
24. Sun J.M., Ahn M.J., Choi Y.L., Ahn J.S., Park K. Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors. Lung Cancer 2013, 82:294-298.
25. Ng K.P., Hillmer A.M., Chuah C.T., Juan W.C., Ko T.K., Teo A.S., et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 2012, 18:521-528.
26. Kim H.R., Cho B.C., Shim H.S., Lim S.M., Kim S.K., Chang J., et al. Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma. Lung Cancer 2014, 83:374-382.
27. Frasca F., Pandini G., Sciacca L., Pezzino V., Squatrito S., Belfiore A., et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 2008, 114:23-37.
28. Samani A.A., Yakar S., LeRoith D., Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007, 28:20-47.
29. Guix M., Faber A.C., Wang S.E., Olivares M.G., Song Y., Qu S., et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008, 118:2609-2619.
30. Vazquez-Martin A., Cufi S., Oliveras-Ferraros C., Torres-Garcia V.Z., Corominas-Faja B., Cuyas E., et al. IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations. Sci Rep 2013, 3:2560.
31. Hurbin A., Wislez M., Busser B., Antoine M., Tenaud C., Rabbe N., et al. Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma. J Pathol 2011, 225:83-95.
32. Masago K., Fujita S., Togashi Y., Kim Y.H., Hatachi Y., Fukuhara A., et al. Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer. Oncol Rep 2011, 26:795-803.
33. Tandon R., Kapoor S., Vali S., Senthil V., Nithya D., Venkataramanan R., et al. Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: a novel approach for overcoming resistance in anticancer treatment. Eur J Pharmacol 2011, 667:56-65.
34. Cortot A.B., Repellin C.E., Shimamura T., Capelletti M., Zejnullahu K., Ercan D., et al. Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. Cancer Res 2013, 73:834-843.
35. Hatlen P., Gronberg B.H., Langhammer A., Carlsen S.M., Amundsen T. Prolonged survival in patients with lung cancer with diabetes mellitus. J Thorac Oncol 2011, 6:1810-1817.
36. Hanbali A., Al-Khasawneh K., Cole-Johnson C., Divine G., Ali H. Protective effect of diabetes against metastasis in patients with non-small cell lung cancer. Arch Intern Med 2007, 167:513.
37. Varlotto J., Medford-Davis L.N., Recht A., Flickinger J., Schaefer E., Shelkey J., et al. Confirmation of the role of diabetes in the local recurrence of surgically resected non-small cell lung cancer. Lung Cancer 2012, 75:381-390.
38. Tseng C.H. Higher risk of mortality from lung cancer in Taiwanese people with diabetes. Diabetes Res Clin Pract 2013, 102:193-201.
39. Inal A., Kaplan M.A., Kucukoner M., Urakci Z., Kilinc F., Isikdogan A. Is diabetes mellitus a negative prognostic factor for the treatment of advanced non-small-cell lung cancer. Rev Port Pneumol 2014, 20:62-68.
40. van de Poll-Franse L.V., Houterman S., Janssen-Heijnen M.L., Dercksen M.W., Coebergh J.W., Haak H.R. Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis. Int J Cancer 2007, 120:1986-1992.
41. Fukuoka M., Wu Y.L., Thongprasert S., Sunpaweravong P., Leong S.S., Sriuranpong V., et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011, 29:2866-2874.
42. Liang W., Zhang Y., Kang S., Pan H., Shao W., Deng Q., et al. Impact of EGFR mutation status on tumor response and progression free survival after first-line chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis. J Thorac Dis 2014, 6:1239-1250.